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Cytoreductive radical prostatectomy 
for newly diagnosed metastatic prostate cancer 
first lessons from the Belgian multicentric LoMP trial 
Reasons for not undergoing cRP were: development of early symptoms due to metastatic disease (n=11), unresectable 
tumor (n=8), refusal to undergo cRP (n=4) or co-morbidity prohibiting cRP (n=6) 
Poelaert F, Buelens S, Rappe B, Plancke H, Stragier J, Martens G, Billiet I, Van Erps T, Kimpe B, Lumen N  
The Local treatment of Metastatic Prostate cancer 
(LoMP) trial provides a framework for the prospective 
evaluation of patients with newly diagnosed metastatic 
prostate cancer (mPCa). 
We report a preliminary analysis of patient’s 
characteristics, safety of cytoreductive radical 
prostatectomy (cRP) and early oncologic results.  
>  cRP appears to be feasible and safe in a group of well selected patients 
Patients were recruited in the context of the Belgian 
multicentric LoMP trial (NCT02138721). 
Seventeen asymptomatic patients with a resectable 
tumor were fit to undergo cRP with extended pelvic 
lymph node dissection. 
A control group of 29 patients received standard of care 
(SoC) therapy only.  
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>  patients are at risk to suffer from local symptoms 
 If only standard of care can be offered 
>  the early oncological results of performing cRP are encouraging 
Median operation time, bloodloss and hospital for cRP were respectively 215min [150-290], 250ml [100-900] and 4d [2-7]. 
Surgical margins were invaded in 14 (82.4%) patients. Respectively 5 (29.4%) and 2 (11.8%) patients suffered a grade 1 and 
2 complication within 30 days postop. Median PSA decline after cRP was 72% ± 18%. 
Median time to castrate-refractory disease was 14 months [95%CI 2-26] in the control group whereas no patient in the 
intervention group developed CRPC (log-rank p=0.006).  
